Lung Cancer

The study authors say their findings argue for careful reading of CT scans done for other reasons that may reveal the presence of lung nodules.

The researchers found that factors favoring chemoimmunotherapy included higher socioeconomic status, being uninsured, a more recent diagnosis and prior glucocorticoid/steroid use.

Study shows that Libtayo plus chemotherapy has lower cost and a larger effect on improving quality-adjusted life years than Keytruda plus chemotherapy as first-line treatment for patients with non-small cell lung cancer.

Study results show that genetic sensitivity to stress was linked to a 49% higher risk of lung cancer in people of European ancestry, and a 45% higher risk in a broader group.

Native Americans face the longest travel times, even after accounting for distances in rural areas, according to results of a recently published cross-sectional study. Lowering transportation barriers could increase screening and early detection.

But many existing models fall short of adhering to established best practices for economic evaluation, the review authors found. Another challenge: Existing models may not be well-suited for evaluating personalized treatments.

By narrowing their research to overweight and obese individuals, Roswell Park researchers found that metformin might offer benefits that previous trials overlooked.

The risk for lung cancer is especially high among those with rheumatoid arthritis who also have interstitial lung disease.

Patients and their caregivers might benefit from being aware of the stigma to advocate for compassionate, optimal care.

Patients with metastatic non-small cell lung cancer, even those with brain metastases, experienced improved longer-term clinical outcomes while on the Opdivo/Yervoy combination compared with those patients receiving chemotherapy alone.

In a new study of patients with metastatic non-small cell lung cancer, researchers found that patients who were more physically fit had better outcomes.

CT scans of the lungs can pick up early-stage lung cancers, but across the nation, less then 20% of those who are eligible are screened.

A benzodiazepine analog produced positive results in a mouse study.

Black patients are less likely than White patients to get the molecular testing that can led to immunotherapy and other more advanced treatments.

Libtayo monotherapy nearly doubled the median overall survival and lowered the risks of death and disease progression.

The data revealed that 17.1% of patients experienced grade 3 or greater arrhythmias.

Researchers that clinical guidelines highlight the possibility of chronic obstructive pulmonary disease and other conditions masking early symptoms of lung cancer.

One of the biggest misconceptions about lung cancer is that it only affects smokers, according to Amy Moore, vice president of Global Engagement and Research Partnerships at LUNGevity.

Obesity is an important modifiable risk factor for developing cancer, second only to tobacco use. Obesity is traditionally defined as having a body mass index (BMI) of 30 kg/m2 or greater, while a BMI of 25 up to 30 kg/m2 is considered overweight.

A recent study highlights a concerning association between missed follow-up appointments and an increased risk of death in people diagnosed with stage I non-small cell lung cancer.

The objective of the study was to project the life-years (LYs) and quality-adjusted LYs for patients eligible for Vitrakvi compared to those receiving a checkpoint inhibitor, Opdivo (nivolumab) or Keytruda (pembrolizumab).

Researchers from the University of Utah in Salt Lake City have developed a more comprehensive, multifaceted digital tool for lung cancer screening that integrates into EHR as well as patient portals. Their paper was published in JAMA Network Open in June 2024.

In a randomized clinical trial, the effectiveness of a stepped-care model for delivering palliative care to patients with advanced lung cancer was evaluated.

Researchers evaluated the association between body composition from readouts generated by cross-sectional imaging and oncologic outcomes in patients with advanced or metastatic NSCLC treated with systemic immunotherapy.

The study evaluated the efficacy and safety of Dato-DXd compared to docetaxel in adult patients with locally advanced or metastatic NSCLC with and without actionable genomic alterations who require systemic therapy following prior treatment.

First approved by the U.S. Food and Drug Administration (FDA) in 2014, Opdivo has multiple indications across various types of cancer, including NSCLC, melanoma, renal cell carcinoma, Hodgkin lymphoma, squamous cell carcinoma of the head and neck, and urothelial carcinoma.